Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Bio-Works Technologies AB announces the launch of WorkBeads affimAb Edge, a new premium resin for the purification of monoclonal antibodies (mAbs). The product is designed to meet the high demands of the rapidly growing biopharmaceutical industry and strengthens Bio-Works' position in the key segment of affinity chromatography.
Strong Market Drivers and Commercial Potential
The market for Protein A resins is estimated at USD 1-1.4 billion annually, with continued growth driven by increasing demand for efficient purification solutions for antibody-based drugs. Protein A resins are a critical component in the purification process, removing up to 90% of impurities.
WorkBeads affimAb Edge combines high capacity, stability, and cost-efficiency with full regulatory documentation. The product is positioned as a competitive alternative to current market leaders and addresses the needs of both innovative drug developers and contract manufacturers (CMOs/CDMOs).
Technical Advantage and Exclusive Partnership
Internal comparison studies show that WorkBeads affimAb Edge outperforms the current leading product in the segment. It is developed and manufactured by Korean company PurioGen Inc., rooted in Bio-Works' long-term partner Amicogen. The partnership is based on a Bio-Works technology license and is executed through an exclusive OEM agreement that ensures control over quality, supply, and brand profile.
"With WorkBeads affimAb Edge, we add a differentiated and competitive product to our portfolio - and take a strategic step toward increasing market share in a high-value segment," says Lone Carlbom, CEO of Bio-Works.
The launch of WorkBeads affimAb Edge is part of Bio-Works' growth strategy focused on high-margin products and global expansion. By combining technical excellence with commercial scalability, the company strengthens its relevance in the value chain for modern biopharmaceuticals.